The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment by Brockmöller Jürgen, Kirchheiner Julia, Schmider Jürgen, Walter Silke, Sachse Christoph, Müller-Oerlinghausen Bruno, Roots Ivar in Clinical pharmacology and therapeutics (2002).

[PMID: 12386646] PubMed


The genetically polymorphic enzyme cytochrome P450 (CYP) 2D6 contributes to the biotransformation of the antipsychotic drug haloperidol. The impact of the polymorphism on haloperidol pharmacokinetics, adverse events, and efficacy was prospectively evaluated under naturalistic conditions in 172 unselected psychiatric inpatients with acute psychotic symptoms.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.